Cassandra Steimle, DO
Gastroenterology · Huber Heights, OHNPI 1265852941
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 990 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 23.3% — the pattern of someone who eats at a lot of different presentations.
Across 990 payments — averaging $16.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$4K
- Takeda Pharmaceuticals U.S.A., Inc.$1K
- Johnson & Johnson$1K
- Bristol Myers Squibb$890
- QOL Medical, LLC$854
- plus $5K from 28 others
Across 114 payments — averaging $7191.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$752K
- Boehringer Ingelheim International GmbH$56K
- Chugai Pharmaceutical Co., Ltd.$4K
- Caris MPI, Inc.$4K
- Madrigal Pharmaceuticals$4K
What the payments were for
- Food & beverage$16,760100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 192 | $3,906 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 293 | $3,708 |
| Takeda Pharmaceuticals U.S.A., Inc. | 93 | $1,428 |
| Johnson & Johnson(2 entities) | 69 | $1,333 |
| Bristol Myers Squibb | 65 | $890 |
| QOL Medical, LLC | 37 | $854 |
| Sanofi | 34 | $669 |
| Pfizer | 31 | $535 |
| Ardelyx, Inc. | 40 | $516 |
| Redhill Biopharma Inc. | 30 | $426 |
| Ipsen Biopharmaceuticals, Inc | 14 | $279 |
| Lilly USA, LLC | 14 | $277 |
| Intercept Pharmaceuticals, Inc. | 8 | $273 |
| Gilead | 11 | $262 |
| Neuraxis, Inc. | 1 | $195 |
| Nestle Healthcare Nutrition Inc. | 9 | $150 |
| E.r. Squibb & Sons, L.L.C. | 2 | $145 |
| Medtronic | 1 | $122 |
| Ironwood Pharmaceuticals, Inc | 9 | $114 |
| Regeneron Healthcare Solutions, Inc. | 4 | $105 |
| Digestive Care, Inc. | 1 | $86 |
| Merck | 6 | $81 |
| Daiichi Sankyo Inc. | 4 | $72 |
| Organon | 4 | $66 |
| Alnylam Pharmaceuticals Inc. | 3 | $47 |
| Evoke Pharma, Inc. | 3 | $42 |
| Ferring Pharmaceuticals Inc. | 2 | $34 |
| Phathom Pharmaceuticals, Inc. | 4 | $34 |
| Fresenius Kabi USA, LLC | 1 | $24 |
| Madrigal Pharmaceuticals | 1 | $21 |
| Tersera Therapeutics LLC | 1 | $19 |
| Boehringer Ingelheim | 1 | $19 |
| Celltrion USA Inc. | 1 | $15 |
| Alfasigma USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$16,760 in reported general payments places this provider in the 85th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EpclusaSofosbuvir/Velpatasvir | 12 | $291,324 |
| SucraidSacrosidase | 12 | $193,581 |
| XifaxanRifaximin | 47 | $146,278 |
| ZenpepLipase/Protease/Amylase | 11 | $67,837 |
| Entyvio PenVedolizumab | 11 | $63,854 |
| CreonLipase/Protease/Amylase | 27 | $58,722 |
| LinzessLinaclotide | 34 | $34,240 |
| Mesalamine | 29 | $15,368 |
| PlenvuPeg3350/Sod Sul/Nacl/Kcl/Asb/C | 98 | $13,574 |
| Ursodiol | 17 | $8,825 |
| Pantoprazole Sodium | 457 | $6,474 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 104 | $6,313 |
| Sucralfate | 55 | $5,919 |
| Budesonide DrBudesonide | 17 | $4,217 |
| Lubiprostone | 14 | $2,968 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadEpclusa | $262 | $291,32412 claims |
| QOL Medical, LLCSucraid | $854 | $193,58112 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Plenvu | $3,708 | $159,851145 claims |
| AbbVieCreon, Linzess | $3,906 | $92,96261 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 657 gastroenterology providers in Ohio.
Other gastroenterology in Huber Heights
- Naim AlkhouriWestlake$1.9M
- Pierre GholamCleveland$1.6M
- Anita AfzaliCincinnati$798K
- Mohamed NaemWestlake$708K
- Kara de FeliceCincinnati$427K
- Tasos ManokasColumbus$411K
- Florian RiederCleveland$396K
- Allan PeckCincinnati$391K
- Dany RaadHighland Hills$387K
- Stanley CohenCleveland$338K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.